Viral replication inhibitors
The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
1. A compound of formula (A),
wherein,
cycle C is
wherein the wavy line ( ) indicates the point of attachment to the carbonyl of the main formula (A) and the hashed line ( ) indicates the point of attachment to the cycle A of the main formula (A);
cycle A is selected from
wherein the wavy line ( ) indicates the point of attachment to the atom of cycle C, and wherein the depicted cycles may be optionally substituted with one, two, or three substituents selected from alkyl, —OCH 3 , halogen, trifluoromethyl, —OCF 3 , or cyano;
cycle B is selected from
wherein the wavy line ( ) indicates the point of attachment to the carbon atom of the main formula (A), and wherein the depicted cycles may be optionally substituted with one, two, or three Z 1a ;
R 1 is selected from, aryl, and heterocycle,
and wherein said, aryl, and heterocycle are optionally substituted with one, two, or three Z 1b ;
R 2 is hydrogen;
R 12 is hydrogen;
R 15 is selected from hydrogen; C 1-6 alkyl; and C 3-7 cycloalkyl;
each Z 1a and Z 1b is independently selected from the group consisting of halogen, hydroxyl, —OZ 2 , ═O, —S(═O) 2 Z 3 , —S(═O) 2 NZ 4 Z 5 , trifluoromethyl, trifluoromethoxy, —NZ 4 C(═O)Z 2 , cyano, C(═O)OZ 2 , C 1-6 alkyl, heteroC 1-6 alkyl, aryl, and heterocycle;
and wherein said C 1-6 alkyl, aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from C 1-6 alkyl, hydroxyl, ═O, halogen, trifluoromethyl, —OCF 3 , and —C(O)OH;
each Z 2 is C 1-6 alkyl;
each Z 3 is independently selected from hydroxyl, and C 1-6 alkyl;
each Z 4 and Z 5 is independently selected from hydrogen, and C 1-6 alkyl;
or an isomer, solvate, or salt thereof;
wherein the term “heterocycle” as used herein means a saturated, unsaturated or aromatic ring system of 3 to 18 atoms including at least one N, O, or S.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound has structure according to formula (E1)
wherein each of cycle A, cycle B, R 12 , R 15 and Z 1b is as described for formula (A) in claim 1 .
4. The compound of claim 1 , wherein the isomer is a stereo-isomer or a tautomer.
5. The compound of claim 1 , wherein the salt is a pharmaceutically acceptable salt.